Principal Financial Group Inc Kezar Life Sciences, Inc. Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$0.8 - $1.05 $4,112 - $5,398	-5,141 Reduced 18.97%	21,966 $19,000
Q4 2023 Feb 07, 2024	SELL	$0.72 - $1.15 $1,371 - $2,190	-1,905 Reduced 6.57%	27,107 $25,000
Q3 2023 Nov 02, 2023	BUY	$1.08 - $2.54 $2,567 - $6,037	2,377 Added 8.92%	29,012 $34,000
Q2 2023 Aug 07, 2023	BUY	$2.31 - $3.06 $22,529 - $29,844	9,753 Added 57.77%	26,635 $65,000
Q1 2023 May 09, 2023	BUY	$3.13 - $7.31 $5,408 - $12,631	1,728 Added 11.4%	16,882 $52,000
Q4 2022 Feb 09, 2023	BUY	$6.39 - $8.8 $25,898 - $35,666	4,053 Added 36.51%	15,154 $106,000
Q3 2022 Nov 09, 2022	BUY	$7.99 - $10.75 $88,696 - $119,335	11,101 New	11,101 $96,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.